CG Oncology reels in $105M crossover for potential late 2024 bladder cancer drug filing
CG Oncology, out to treat bladder cancer patients left behind by the shortage of Merck’s standard BCG therapy or didn’t benefit from it in the first place, has reeled in a $105 million crossover financing.
The California biotech anticipates a Phase III topline readout for a monotherapy version of its oncolytic virus candidate by year’s end and then a regulatory approval filing in late 2024 or early 2025, CEO Arthur Kuan told Endpoints News in a preview of the funding round, which was disclosed Wednesday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.